2 Small-Cap Stocks Worth Investigating and 1 We Avoid
Small-cap stocks can offer investors exposure to businesses that still have plenty of room to grow, but the opportunity comes with significantly higher risk. Smaller companies can face weaker balance sheets, greater earnings volatility and sharper share-price swings than established large-cap businesses.
As of August 2026, two U.S. small-cap names stand out for further investigation: Arlo Technologies (NYSE: ARLO) and Alignment Healthcare (NASDAQ: ALHC). Both have recently reported strong operating momentum. By contrast, The Lovesac Company (NASDAQ: LOVE) deserves a more cautious approach because its recent growth profile remains relatively modest and the consumer-discretionary business is sensitive to changes in household spending.
This is not a list of guaranteed winners or an instruction to buy or sell. Instead, the goal is to examine what is improving, what could go wrong and which numbers investors should monitor next.
1. Arlo Technologies: A Small-Cap Smart-Home Company Worth Watching
Arlo Technologies operates in the connected-home security market, selling cameras, doorbells, security systems and related subscription services.
Its latest numbers provide one of the strongest reasons to investigate the stock further.
For the second quarter of 2026, Arlo reported record revenue of $156 million, up 21% year over year. More importantly, subscriptions and services revenue reached a record $93 million, increasing 19% from a year earlier. The company also reported GAAP net income of $3 million and adjusted EBITDA of $31 million.
The shift toward subscription revenue matters because recurring services can potentially provide more predictable economics than one-time hardware sales.
Why Arlo Looks Interesting
Arlo's business is gradually becoming less dependent on simply selling cameras.
Its subscription services allow the company to generate recurring revenue from customers after they purchase its hardware. That creates an opportunity to increase the lifetime value of each customer if subscribers remain on the platform.
The latest quarter also showed improving profitability. Arlo's GAAP gross margin reached 48%, up 330 basis points year over year, while non-GAAP gross margin reached 51%. Adjusted EBITDA margin was 20%.
That combination—double-digit revenue growth, subscription expansion and improving margins—is worth monitoring.
The Risk
Arlo is still operating in a highly competitive smart-home market.
Large technology companies and established security brands have substantial resources, while consumers can choose from a wide range of inexpensive cameras and connected devices.
Investors should therefore watch whether subscription growth continues and whether margin expansion is sustainable. Hardware demand alone is not enough to justify a long-term growth thesis.
2. Alignment Healthcare: Strong Growth in Senior Healthcare
Alignment Healthcare is a healthcare company focused on Medicare Advantage plans for seniors in the United States.
Its recent financial performance has been particularly notable.
For the second quarter of 2026, Alignment Healthcare generated $1.3 billion in revenue, representing 31.6% year-over-year growth. Medicare Advantage membership increased 31.5% to approximately 294,100 members. The company also raised the midpoint of its full-year guidance for membership, revenue, adjusted gross profit and adjusted EBITDA.
The company expects full-year 2026 revenue of between $5.195 billion and $5.225 billion, while adjusted EBITDA guidance stands at $145 million to $163 million.
For a small-cap company, that rate of expansion is difficult to ignore.
Why Alignment Healthcare Stands Out
The most important factor is membership growth.
Healthcare businesses can benefit from scale because a growing member base can increase revenue while technology and operational investments are spread across more customers.
Alignment also says it is using technology and an AI-enabled platform as part of its healthcare model. Its business is built around coordinated care for seniors rather than simply functioning as a traditional insurance provider.
The company generated $3.95 billion in total revenue in fiscal 2025, up 46.1% from the previous year, according to its investor-relations materials. It also rose to No. 791 on the 2026 Fortune 1000 list.
What Could Go Wrong?
Healthcare is a heavily regulated industry, and Medicare Advantage economics can change with government policies, reimbursement rates and medical costs.
Rapid membership growth also needs to translate into sustainable profitability. Investors should therefore focus not only on revenue growth but also on adjusted EBITDA, medical-cost trends, cash generation and membership retention.
In other words, growth is attractive, but profitable growth is what matters over the long term.
1 Small-Cap Stock We Would Approach With Caution: Lovesac
The Lovesac Company is a specialty furniture company best known for its modular Sactionals seating system.
There are positive elements to the business, including its differentiated products and ongoing efforts to expand its brand. However, its recent growth profile does not look as compelling as the two companies above.
Lovesac reported fiscal 2026 net sales of $697.1 million, up only 2.4% year over year. Fourth-quarter sales increased 2.7% to $248 million. The company also announced a new $40 million share-repurchase authorization.
The company is attempting to broaden its product range and evolve from a product-focused furniture business into a wider lifestyle brand. Management has also discussed new seating platforms and plans to bring a higher-end sectional-sofa platform to market.
Those initiatives could eventually improve growth, but investors have to pay attention to execution.
Why We Are Cautious on LOVE
The biggest issue is the contrast between the company's ambitions and its current growth rate.
Revenue growth of just 2.4% in fiscal 2026 suggests that the business still has to prove it can return to a stronger growth trajectory.
Furniture is also discretionary spending. When consumers become concerned about inflation, employment or household finances, large-ticket purchases can be delayed.
That makes the company more economically sensitive than businesses providing essential healthcare services or recurring technology subscriptions.
Lovesac does have strategic initiatives underway, and its share-repurchase authorization could support shareholder returns if the company generates sufficient cash. But buybacks alone do not solve a weak growth environment.
For now, the stock appears to require more evidence that new products and the broader brand strategy can translate into stronger sales and profitability.
Small-Cap Stocks: What Investors Should Actually Look For
The biggest mistake investors make with small-cap stocks is focusing only on the potential upside.
A company growing quickly can still be a poor investment if it burns too much cash, carries excessive debt or trades at an unrealistic valuation.
For stocks such as Arlo and Alignment Healthcare, investors should monitor:
- Revenue growth and whether it is accelerating or slowing
- Free cash flow and cash conversion
- Operating and gross margins
- Balance-sheet strength
- Customer or membership growth
- Competitive positioning
- Management's full-year guidance
- Valuation relative to realistic earnings growth
For Lovesac, the key question is different: Can the company restart meaningful growth while maintaining healthy profitability and cash generation?
The Bottom Line
Arlo Technologies and Alignment Healthcare currently offer two very different small-cap growth stories.
Arlo is benefiting from rising subscription revenue, improving margins and continued demand for connected-home security products. Its Q2 2026 results provide evidence that the business is becoming more profitable as recurring services expand.
Alignment Healthcare has an even faster growth profile, with revenue and Medicare Advantage membership both increasing by more than 30% year over year in Q2 2026. The company has also raised its full-year guidance midpoint.
Lovesac, meanwhile, is not necessarily a broken business, but its 2.4% fiscal 2026 sales growth makes it harder to justify the same level of enthusiasm. The company needs to demonstrate that its new products and broader lifestyle strategy can produce stronger growth.
For investors, the takeaway is simple: small-cap investing is less about finding the stock with the most exciting story and more about identifying businesses where growth, cash flow and competitive advantages are improving together.
The next earnings reports from these companies will be important in determining whether the current trends are temporary or the beginning of a more durable change.
Follow our blog for more small-cap stock analysis, U.S. market updates, earnings coverage and investor-focused business news.
This article is for informational and educational purposes only and should not be considered investment advice
Comments
Post a Comment